Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Falling Comet
1394.9000 -15.30 (-1.08%)
NSE Jan 16, 2026 14:15 PM
Volume: 410.0K
 

1394.90
-1.08%
Emkay
DLPL reported a steady Q4, with EBITDA beating street/our estimates by 6% and adj PAT improving 34% on YoY basis. Strong performance in core markets (Delhi NCR), buoyed by network expansion, offset the persistent muted performance of Suburban (mid-single digit revenue growth).
Number of FII/FPI investors increased from 358 to 391 in Sep 2025 qtr.
More from Dr. Lal Pathlabs Ltd.
Recommended